Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Current Quarter	$-2.19	Next Quarter	$NA
Current Year	$-11.36	Next Year	$-4.18
QoQ Growth	NaN%	YoY Growth	+63.2%
3Y EPS CAGR	+75.1%	Target Price	$32.50
Consensus	Buy	Upside	+231.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PASG	$9.80	-8.29%	77.35K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PASG	$9.80	-8.3%	77.35K
3
4
5
6

PASG

PASG

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Passage Bio Inc. Data in Excel

Get Passage Bio Inc. Data in Excel